Table 1.
Patient characteristics
| Characteristics | Total sample n = 939 n (%) |
|
|---|---|---|
| Mean age (years± SD) | 58.6 (11.9), range:19–88 | |
| Sex | ||
| Women (%) | 562 | (59.9) |
| Men (%) | 377 | (40.1) |
| Cancer sites | ||
| Breast cancer | 277 | (29.5) |
| Hemato-oncological malignancy | 99 | (10.5) |
| Colorectal cancer | 94 | (10.0) |
| Head and neck cancer | 62 | (6.6) |
| Prostate cancer (including penis and testes) | 57 | (6.1) |
| Gastric cancer (including esophagus) | 52 | (5.5) |
| Gynecological cancer | 44 | (4.7) |
| Lung cancer | 43 | (4.6) |
| Pancreatic cancer (including liver and gall bladder) | 34 | (3.6) |
| Urinary organs | 34 | (3.6) |
| Brain cancer | 14 | (1.5) |
| Others | 68 | (7.2) |
| Missing data | 61 | (6.5) |
| HADS total score | ||
| Mean (SD) | 11.9 | 7.2 |
| Psychotherapeutic pretreatment | ||
| Yes | 204 | (21.7) |
| No | 726 | (77.3) |
| Missing | 9 | (1.0) |
| Preference for psycho-oncological focus | ||
| Yes | 453 | (48.2) |
| No | 477 | (50.8) |
| Missing | 9 | (1.0) |
| Preferred psycho-oncological focus | ||
| Sexual psychology | 49 | (10.8) |
| Existential analysis | 130 | (28.7) |
| Biofeedback | 99 | (21.9) |
| No preference | 127 | (28.0) |
| Missing | 48 | (10.6) |